Advanced search
Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 30, 2023 - Issue 3
Submit an article Journal homepage
209
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis

Mitsuto Satoa Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, JapanView further author information
,
Yusuke Mochizukia Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, JapanView further author information
,
Yusuke Takahashia Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, JapanView further author information
,
Ken Takasonea Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, JapanView further author information
,
Emre Aldincb Alnylam Pharmaceuticals, Cambridge, MA, USAView further author information
,
Simina Ticaub Alnylam Pharmaceuticals, Cambridge, MA, USAView further author information
,
Gang Jiab Alnylam Pharmaceuticals, Cambridge, MA, USAView further author information
&
Yoshiki Sekijimaa Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, Japan;c Institute for Biomedical Sciences, Shinshu University, Nagano, JapanCorrespondence[email protected]
View further author information
 show all
Pages 351-352 | Received 03 Feb 2023, Accepted 28 Feb 2023, Published online: 12 Mar 2023
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days
"Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis." Amyloid, 30(3), pp. 351–352

Disclosure statement

This study is being conducted as a research collaboration with Alnylam Pharmaceuticals. Yoshiki Sekijima received speaker honoraria from Alnylam Pharmaceuticals and Pfizer.

Additional information

Funding

Funding has been received from Alnylam Pharmaceuticals for the conduction of this study as a part of the research collaboration agreement.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.